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ABSTRACT:
T-cell acute lymphoblastic lymphomas commonly demonstrate activating Notch1 mutations as well as mutations or deletions in Fbxw7. However, since Fbxw7 targets Notch1 for degradation, genetic alterations in these two genes are expected to be mutually exclusive events in lymphomagenesis. Previously, using a radiation-induced Tp53-deficient mouse model for T-cell acute lymphoblastic lymphoma, we reported that loss of heterozygosity at the Fbxw7 locus occurs frequently in a Tp53-dependent manner. In the current study, we show that these thymic lymphomas also commonly exhibit activating Notch1 mutations in the proline-glutamic acid-serine-threonine (PEST) domain. Moreover, concurrent activating Notch1 PEST domain mutations and single copy deletions at the Fbxw7 locus occur with high frequency in the same individual tumors, indicating that these changes are not mutually exclusive events. We further demonstrate that while Notch1 PEST domain mutations are independent of Tp53 status, they are completely abolished in mice with germline Fbxw7 haploinsufficiency.
Therefore, Notch1 PEST domain mutations only occur when Fbxw7 expression levels are intact. These data suggest a temporal sequence of mutational events involving these important cancer-related genes, with Notch1 PEST domain mutations occurring first, followed by Fbxw7 deletion, and eventually by complete loss of Tp53.
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From
INTRODUCTION:
Activating Notch1 mutations occur in more than 50% of human T-cell acute lymphoblastic lymphomas (T-ALLs).
1 Comparable mutations arise in murine thymic lymphomas generated in genetically sensitized mouse models. 2, 3 These genetic alterations occur exclusively in the heterodimerization (HD) and proline-glutamic acidserine-threonine (PEST) domains of Notch1, resulting in elevated levels of intracellular domain of Notch1 (ICN). HD domain mutations lead to unsolicited release of ICN, 4 while PEST domain mutations prevent Fbxw7-mediated turnover of ICN.
5-9
The mechanism by which elevated ICN levels lead to lymphomagenesis is not entirely clear. Some evidence suggests that elevated ICN may inhibit p19-Arf, leading to increased Mdm2-mediated degradation of Tp53. 10 If indeed this pathway plays an important role in lymphomagenesis, activating Notch1 mutations and loss of Tp53 activity are expected to be mutually exclusive genetic events. Consistent with this hypothesis, a large-scale retroviral insertional mutagenesis screen demonstrated that
Notch1 mutations occur more frequently in tumors from wildtype mice than from their Tp53-deficient counterparts.
11
Genetic alterations in Fbxw7 are also commonly found in human T-ALL and murine thymic lymphomas. 129/Sv mice. Three animals for each genotype were used. Total RNA and cDNA synthesis were performed as described above. Fbxw7 expression levels were determined using the TaqMan Gene Expression Assay for mouse Fbxw7 on a 7900 HT Fast Real-Time PCR System (Applied Biosystems, Carlsbad, CA). Beta-actin expression was used as an endogenous control.
RESULTS:
Notch1 PEST domain mutations are independent of Tp53 status:
Since activating Notch1 mutations may be mutually exclusive toTp53 inactivation, 10,11,21 we examined whether Notch1 mutations occur in thymic lymphomas 12 Thus, genetic changes in Fbxw7 must precede complete loss of the wild type Tp53 allele. These conclusions suggest a model of thymic lymphoma development involving early stage activation of Notch1 through mutations to the PEST domain, followed by Fbxw7 deletion/mutation, and late loss of the remaining Tp53 allele (Figure 2A ). In contrast, Fbxw7 heterozygous mice can bypass the requirement for Notch1 PEST domain mutations, since Fbxw7 expression levels are compromised, and proceed directly to eliminate Tp53 activity to yield malignant transformation ( Figure 2B ). Currently, although many common genetic alterations have been reported in numerous tumor types, the sequence in which these mutational events occur during tumorigenesis remains largely unknown. In this study, we are able to establish the sequential order of a few key mutational events during lymphomagenesis by examining the frequency of these genetic alterations in tumors from various genetically engineered mouse models. Additional studies using this strategy may help further establish a chronological description of other genetic mutations that contribute to tumor development.
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